GlassScriptPhysician profile
Alexis W Buffington
NPI 1407389406
$7,627.98
in general payments reported to CMS, 2019-2025
24 companies · $2,121 in 2025
The $2,121 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $122 · 2021: $530 · 2022: $1,570 · 2023: $1,559 · 2024: $1,726 · 2025: $2,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,094 · Education: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,093.86 |
| Education | $312.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,202.78 | 2020-2025 | Rinvoq, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $809.55 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $689.20 | 2020-2025 | |
| Arcutis Biotherapeutics, INC. | $578.66 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $548.84 | 2022-2024 | Vtama |
| Ucb, INC. | $473.11 | 2021-2025 | Bimzelx |
| Genzyme Corporation | $422.67 | 2022-2025 | |
| Janssen Biotech, INC. | $400.95 | 2022-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $383.37 | 2022-2023 | |
| Pfizer INC. | $351.77 | 2020-2025 | |
| Lilly USA, LLC | $342.68 | 2023-2025 | Ebglyss, Olumiant, Taltz |
| Galderma Laboratories, L.P. | $303.75 | 2024-2025 | Aklief, Nemluvio |
| Janssen Scientific Affairs, LLC | $243.10 | 2021-2022 | |
| Amgen INC. | $206.56 | 2022-2025 | Otezla, Otezla |
| Incyte Corporation | $192.09 | 2022-2025 | Opzelura |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $135.77 | 2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.32 | 2023 | Spevigo |
| Organon LLC | $67.55 | 2025 | Vtama |
| Leo Pharma INC. | $57.24 | 2022-2025 | Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $36.16 | 2023-2024 | Duobrii, Siliq, Jublia |
| Biofrontera INC. | $25.77 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Kyowa Kirin, INC. | $21.99 | 2022 | |
| Almirall LLC | $14.17 | 2021 | |
| Biodermis LLC | $11.93 | 2025 | Pro-Sil, Biocorneum, Epi-Derm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Buffington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.